Characteristics | CML Patients | p value | |
IM Responders (n = 22) | IM non-responders (n = 26) | ||
Sex Males/females | 9/13 | 13/13 | 0.76 |
Age at diagnosis (y) mean (range) | 49.0 (23 - 80) | 44.1 (24 - 62) | 0.22 |
Transcript type |
|
|
|
b2a2, N | 5 | 11 | 0.18 |
b3a2, N | 17 | 14 | 0.60 |
b2a2 + b3a3, N | 0 | 1 | 0.45 |
Sokal score |
|
|
|
Low, N | 7 | 11 | 0.32 |
Intermediate, N | 8 | 10 | 0.83 |
High, N | 7 | 5 | 0.79 |
Achievement of CCyR within 6 months, N | 22 | 10 | 0.36 |
Treated with dasatinib, N | - | 10 | - |
Treated with nilotinib, N | - | 16 | - |
Primary failure of IM, N | - | 20 | - |
Secondary failure of IM, N | - | 6 | - |